Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 367, Issue 2, 2003, Pages 134-139

  Peinado, J ^a   Hameg, A ^b   Garay, R P ^c   Bayle, F ^d   Nuss, P ^e   Dib, M ^b  

^a UNIVERSITY OF GRANADA   (Spain)

^b SANOFI   (France)

^c FACULTÉ DE MÉDECINE   (France)

^d INSERM   (France)

^e HÔPITAL SAINT ANTOINE   (France)

Author keywords

Cyamemazine; Dopamine; Microdialysis; Rat; Serotonin; Striatum

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; CYAMEMAZINE; DOPAMINE; HOMOVANILLIC ACID; POTASSIUM ION;

ANIMAL EXPERIMENT; ARTICLE; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINE RELEASE; DRUG EFFECT; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MALE; NONHUMAN; RAT; SEROTONIN METABOLISM;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HOMOVANILLIC ACID; HYDROXYINDOLEACETIC ACID; INJECTIONS, INTRAPERITONEAL; MALE; MICRODIALYSIS; PHENOTHIAZINES; RATS; RATS, WISTAR; TIME FACTORS;

EID: 0037291720     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-002-0665-4     Document Type: Article

References (27)

1. Alcantara AG, Barcia D (1999) Risperidone and concept of bipolar neuroleptic. Encephale 25:146-150
2. 2C-receptor antagonist properties of cyamemazine: significance for its clinical anxiolytic activity. Psychopharmacology 147:412-417
3. 2A-receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle. Eur J Pharmacol 454:235-239
4. Bhana N, Foster RH, Olney R, Plosker GL (2001) Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 61:111-161
5. Bourin M, Dhonnchadha BAN, Colombel MC, Dib M, Hascoët M (2001) Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice. Behav Brain Res 124:87-95
6. De Klippel N, Sarre S, Ebinger G, Michotte Y (1993) Effect of M1- and M2-muscarinic drugs on striatal dopamine release and metabolism: an in vivo microdialysis study comparing normal and 6-hydroxydopamine-lesioned rats. Brain Res 630:57-64
7. 2C receptors in the control of central dopamine function. Trends Pharmacol Sci 22:229-232
8. Di Matteo V, Cacchio M, Di Giulio C, Di Giovanni G, Esposito E (2002) Biochemical evidence that the atypical antipsychotic drugs clozapine and risperidone block 5)HT(2C) receptors in vivo. Pharmacol Biochem Behav 71:607-613
9. Dubroca JM (1989) L'anxiolyse: intérêt de la cyamémazine. NeuroPsy :4-7
10. 3 receptor agonists on voluntary ethanol intake in rats maintained on a limited access procedure. Alcool 32:455-462
11. Garay RP, d'Alché-Birée F (1995) Cyamémazine (Tercian®): profil neuroleptique ou anxiolytique ?. Inf Psychiatr 10:969-970
12. Hernandez L, Hoebel BG (1995) Chronic clozapine selectively decreases prefrontal cortex dopamine as shown by simultaneous cortical, accumbens, and striatal microdialysis in freely moving rats. Pharmacol Biochem Behav 52:581-589
13. Herrick-Davis K, Grinde E, Teitler M (2000) Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine 2C receptors. J Pharmacol Exp Ther 295:226-232
14. Ichikawa J, Meltzer HY (1995) DOI, a 5-HT2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum. Brain Res 698:204-208
15. Invernizzi R, Pozzi L, Samanin R (1995) Selective reduction of extracellular dopamine in the rat nucleus accumbens following chronic treatment with DAU 6215, a 5-HT3 receptor antagonist. Neuropharmacology 34:211-215
16. Julou L, Ducrot R, Fournel J, Lean O, Bardone MC, Myon J (1961) Etude des propriétés pharmacologiques de la cyano-3 (diméthyl-3' méthyl-2 propyl)-10 phénotiazine ou cyamépromazine (7.204 R.P.) Comptes Rendus Soc Biol 155:1029-1034
17. Lidow MS, Goldman-Rakic PS (1997) Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. J Pharmacol Exp Ther 283:939-946
18. Lucas G, De Deurwaerdère, Caccia S, Spampinato U (2000) The effect of serotoninergic agents on haloperidol-induced striatal dopamine release in vivo: opposite role of 5-HT2A and HT2C receptor subtypes and significance of the haloperidol dose used. Neuropharmacology 39:1053-1063
19. Meltzer HY (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21 [Suppl 2]:106S-115S
20. Ng NK, Lee HS, Wong PT (1999) Regulation of striatal dopamine release through 5-HT1 and 5-HT2 receptors. J Neurosci Res 55:600-607
21. Pehek EA, Yamamoto BK (1994) Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen. J Neurochem 63:2118-2124
22. Radat F (1995) Cyamémazine: traitement symptomatique des dimensions anxieuses, impulsives et agressives. Inf Psychiatr 10:967-968
23. Sibley DR (1999) New insights into dopaminergic receptor function using antisense and genetically altered animals. Annu Rev Pharmacol Toxicol 39:313-341
24. Sotnikova TD, Gainetdinov RR, Grekhova TV, Rayevsky KS (2001) Effects of intrastriatal infusion of D2 and D3 dopamine receptor preferring antagonists on dopamine release in rat dorsal striatum. Pharmacol Res 43:283-290
25. Starke K, Göthert M, Kilbinger H (1989) Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 69:864-989
26. Strange PG (2001) Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 53:119-133
27. Waters N, Lagerkvist S, Löfberg L, Piercey M, Carlsson A (1993) The dopamine D3 receptor and autoreceptor preferring antagonists (+)-AJ76 and (+)-UH232; a microdialysis study. Eur J Pharmacol 242:151-163